clinical trial · NCT06794541
A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)
Tetraphase Pharmaceuticals, Inc·phase2·recruiting·n = 35
Complicated Intra-abdominal Infections (cIAI)Eravacycline 2mg/kgEravacycline 1.5mg/kg
brief summary
A Phase 2 trial to assess safety, tolerability, and pharmacokinetics of eravacycline in pediatric patients aged 8 to \<18 years with cIAI.
started
May 22, 2025
primary completion
Feb 17, 2029
completion
Mar 19, 2029
last updated
Oct 29, 2025
official title
Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Intravenous Eravacycline in Pediatric Patients From 8 Years to Less Than 18 Years of Age With Complicated Intra-abdominal Infections (cIAI)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol